Maiden Holdings, Ltd. (MHLA) stock intrinsic value fair value estimate & owner earnings analysis

WHAT THIS SECURITY IS. MHLA is not a share of stock. It is Maiden Holdings, Ltd.'s 6.625% Senior Notes due June 2046, sold in $25 units. Each unit pays $1.66 of interest a year and $25 at maturity, and the issuer can redeem it at $25 at any time. There is $110.0 million of these notes outstanding. Maiden's common shares stopped trading on May 27, 2025, when Maiden combined with Kestrel Group and became its wholly owned subsidiary. Kestrel Group Ltd (Nasdaq: KG) has fully and unconditionally guaranteed the notes, but it is a holding company too: its own business adds very little money. The values below are per $25 note. THE BUSINESS BEHIND THE NOTES. Maiden is a Bermuda reinsurer in run-off. Most of its remaining liabilities come from the AmTrust quota share and a European hospital liability contract, both terminated. Its main operating company is Maiden Reinsurance, regulated in Vermont, and a large part of those old claims is covered by a 2019 loss portfolio transfer and adverse development cover with Cavello Bay (an Enstar company). Kestrel adds a small program-services fee business: $6.1 million of fee revenue in 2025, 72% of it from a single client. Nothing in the filings shows it is big enough to change the picture for the notes. EARNING POWER. Owner earnings count the cash the business generates from operations, stripping out claim payments from old reserves (which reflect past underwriting, not current earning power) and deducting stock compensation and preferred dividends. On that basis Maiden earned about $1.14 per share in 2015 and has been negative in six of the eight years since: -$5.64 in 2018, -$0.52 in 2023 and -$2.23 in 2024, when it strengthened reserves and lost $201 million. It has had no positive earnings level to anchor on for a decade. After the combination, Kestrel Group lost about $14 million on its own operating measure in 2025, even after excluding a $68 million one-time accounting gain from buying Maiden cheaply. It then lost $15.5 million in the first half of 2026. The combined group loses roughly $10 million a year before interest, and cash interest on its two note issues is $19.1 million a year. So the notes are not being serviced from earnings. They are being serviced by gradually drawing down Maiden Reinsurance's capital. THE ASSETS THAT PAY THE NOTES. Kestrel's 10-K says the holding company depends completely on dividends from Maiden Reinsurance to pay interest on both note issues, and every dividend needs prior approval from the Vermont regulator. At the end of 2025 Maiden Reinsurance had $258.0 million of statutory capital against a required $55.0 million. It paid $28.8 million of approved dividends in 2025 and $7.5 million in February 2026. Group unrestricted cash and bonds were only $16.3 million at year-end 2025, and much of the investment portfolio is illiquid private investments that management is trying to sell. On the June 30, 2026 balance sheet, shareholders' equity was $114.0 million. However, that figure carries the $262.4 million of notes at only $175.0 million, the market-based value set at the acquisition. Counting the notes at the full amount owed leaves about $27 million of equity, which is being used up at close to $27 million a year. TWO NAMED RISKS. First, Cavello disputes the loss dates on $46.7 million of identified claims and about $25 million of possible further claims under the adverse development cover. If Cavello wins, Maiden Reinsurance's capital falls by up to about $72 million. Second, holders of the 7.75% 2013 Senior Notes (issued by Maiden's US subsidiary) have sued, claiming those notes are due now. A New York court dismissed the first suit in June 2025, but it is under appeal and a second suit is pending. Because those notes sit closer to Maiden Reinsurance, they would be paid before MHLA in any wind-down. The same is true of an intercompany loan Maiden Holdings owes Maiden Reinsurance. MHLA holders would recover only what is left after that. THE CASES (discounted at 6%). Base case, $8.05. Maiden Reinsurance's excess capital of about $200 million keeps paying about $25-30 million a year in approved dividends until roughly the end of 2031. The run-off keeps losing money at the recent pace, and no new business large enough to matter is counted, because none is signed or proven. Interest stops around then. MHLA holders recover about 5% of face (around $1.25 per note) a couple of years later, because what is left goes first to the 2013 notes. Year one assumes the same losses as the last twelve months, with no improvement credited. Bear case, $2.90. The Cavello dispute goes against Maiden, and further reserve increases like those in 2018 and 2024 follow. Or a court accelerates the 2013 notes. Either way, the Vermont regulator stops approving dividends, and interest stops around the end of 2027. Recovery is about 5% of face, several years later. Bull case, $13.65. Cavello is settled on Maiden's terms, reserves run off without more bad surprises, cost cuts already under way hold, and the private investments sell near their carrying values. That stretches interest payments to about 2036, with about 10% recovered after that. Paying every coupon through 2046 would be worth about $26.80 at 6%. That is not counted in any case: it would need the group to become consistently profitable, which depends on Kestrel's program business growing far beyond anything it has done. Because the notes can be redeemed at $25 at any time, value above $25 could not be counted on in any case either. ACCOUNTING JUDGEMENTS. The notes are valued on the cash they are owed, not the discounted book value Kestrel carries them at. The group's equity was therefore restated with the notes at their full $262.4 million, which removes about $87 million of apparent cushion. Unrealized investment gains and the one-time $68 million acquisition gain were excluded from earning power. WHAT WOULD MAKE THIS WRONG. On the upside: a signed settlement with Cavello, a capital raise or sale of Kestrel that brings in outside money, or Kestrel's program business growing into real profits. On the downside: a court accelerating the 2013 notes, or the Vermont regulator refusing a dividend request. Filings after the first half of 2026 were not available, so any change since August 2026 in the Cavello dispute or the 2013 notes lawsuits is not reflected here.